Vaxcyte, Inc. (PCVX)

NASDAQ • Healthcare

$58.77

-$0.43 (-0.7%)

Market closed

Last close at September 16, 2026 at 20:00 UTC

Open$59.25

Day Range$58.4 - $60.13

Avg. Volume (3M)1.1M

Market Cap$8.4B

52 Week Range

$30.81$65

Next EarningsIn 48 daysNov 3, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$1B

EPS (TTM)

-$7.64

ROA (TTM)

-33.91%

Current Ratio

5.72

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-8.9%Q3 2025-$1.22

-22.8%Q4 2025-$1.56

-17.7%Q1 2026-$1.8

-29.4%Q2 2026-$2.3

+4.4%Q3 2026-$1.97

Nov 3

in 48 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +4.4%

Vaxcyte, Inc. topped EPS consensus in the fiscal second quarter of 2026, with EPS of -$1.97 versus a -$2.06 estimate, +4.4%, in preliminary results reported August 5, 2026. The quarter also showed an operating loss of about $302.8 million and a net loss of about $284.3 million, with net income down 70.7% from a loss of $166.6 million a year ago and EPS down 61.5% from -$1.22. Operating cash flow was negative about $513.1 million. Next-period consensus calls for EPS of -$2.12 on revenue of $12.5 million.

View full earnings history

About Vaxcyte, Inc.

Vaxcyte, Inc. trades on the NASDAQ as PCVX and operates in biotechnology within the healthcare sector. The company is a clinical development-stage vaccine maker that develops protein-based candidates to prevent or manage bacterial infectious diseases, rather than a commercial drug business with product revenue.

Name

Vaxcyte, Inc.

CEO

Grant E. Pickering

Website

vaxcyte.com

Industry

Healthcare

Year Founded

2013

Employees

507

Today's Snapshot

AI-generated

The day ended with PCVX 0.7% lower at 58.77, while its sector was flat.

Trading Volume

Above 10d avg 1.2M

1.2M

vs S&P 500 Today

Moderate Underperformance

-0.16%

Updated: September 16, 2026 at 20:26 UTC

Technical Indicators

4 Buy2 Neutral2 Sell

PCVX shows a mild buy stance underpinned by a discernible trend and longer-term support, while short-term momentum is mixed. The ADX around the mid-20s indicates a modest trend, and the stock sits above its 50- and 200-day averages but just below the short 10/20-day moving averages, suggesting a near-term pullback inside a broader uptrend. Momentum oscillators are conflicted—stochastic and Williams readings point toward short-term oversold conditions while RSI and MACD are neutral—and volatility is moderate with ATR near 3.5%. Weak OBV implies limited volume backing the move. Technical takeaway: Buy.

All signals